Needlestick Injury Protocol: Immediate Steps, Reporting, and PEP

A prompt, structured response to a sharps exposure limits the risk of bloodborne pathogen transmission and aligns your facility’s Occupational Exposure Protocol. This guide walks you through Immediate Steps, Reporting, and Post-Exposure Prophylaxis (PEP) so you can act decisively and document accurately.

Immediate Wound Care

First actions

• Remove gloves carefully and secure the device without recapping; place it in an approved sharps container.
• For percutaneous injury: wash the site promptly with soap and running water; allow it to bleed freely without forceful squeezing.
• For mucous membrane splash: irrigate eyes, nose, or mouth with copious water or normal saline; remove contact lenses before eye irrigation.
• Cover the area with a clean dressing and replace contaminated clothing or PPE.

What to avoid

• Do not cut, squeeze aggressively, or scrub the wound.
• Do not apply caustic agents (e.g., bleach) or inject antiseptics into the wound.

Infection Control Measures

• Decontaminate affected work surfaces promptly and follow facility spill procedures.
• Perform hand hygiene before and after care; don fresh PPE as needed.
• Record the exposure details immediately to support Sharps Injury Reporting and later Serological Testing.

Reporting the Incident

Notify and document without delay

Report the exposure at once to your supervisor and occupational health or the designated exposure hotline. Early reporting enables rapid risk assessment, timely PEP, and complete Sharps Injury Reporting within your shift.

Information to capture

• Date/time, location, activity performed, and Infection Control Measures in place.
• Device type (e.g., hollow-bore needle), gauge, visible blood, and depth of injury.
• Whether the device was used in a vein/artery and if blood was injected.
• Source patient identifiers per policy and any known infection status or risk factors.
• Your HBV vaccination status and prior anti-HBs results, medications, pregnancy status, and allergies.

Complete internal Occupational Exposure Protocol forms fully and maintain confidentiality for both the exposed worker and the source patient.

Post-Exposure Prophylaxis Initiation

Timing and decision-making

• Start HIV Post-Exposure Prophylaxis (PEP) as soon as possible—ideally within 2 hours and generally no later than 72 hours after exposure.
• Do not delay PEP while awaiting source patient results; PEP can be discontinued if the source is later confirmed negative.

HIV antiretroviral regimen

Use a three-drug Antiretroviral Regimen for 28 days unless advised otherwise by an expert. Common first-line options include:

• Tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg once daily PLUS dolutegravir 50 mg once daily; or
• Tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg once daily PLUS raltegravir 400 mg twice daily.

• Obtain baseline renal/hepatic function and pregnancy testing where appropriate.
• Review drug–drug interactions and comorbidities; adjust for renal impairment.
• Provide counseling on adherence, side effects, and follow-up Serological Testing.

Hepatitis B management (HBIG and vaccination)

• If you are immune (documented anti-HBs ≥10 mIU/mL): no post-exposure intervention is needed.
• If vaccination status is unknown or anti-HBs is unknown: draw anti-HBs. If inadequate (<10 mIU/mL), give Hepatitis B Immune Globulin (HBIG) 0.06 mL/kg IM as soon as possible (preferably within 24 hours; effective window up to 7 days) and give a vaccine dose, then complete the series.
• If unvaccinated: administer HBIG 0.06 mL/kg IM promptly and start the HBV vaccine series; complete all doses on schedule.
• If a documented vaccine nonresponder (anti-HBs <10 after two complete series) and source is HBsAg-positive or unknown: give two HBIG doses one month apart.

Hepatitis C exposure

No PEP is recommended for HCV. Emphasize early detection: obtain baseline tests and schedule HCV RNA at 3–6 weeks, with definitive serology later. If acute infection occurs, refer promptly for direct-acting antiviral therapy.

Baseline serological testing and labs

• HIV Ag/Ab (4th generation), HBV serologies (anti-HBs; consider HBsAg/anti-HBc as indicated), and HCV antibody with reflex RNA if positive.
• ALT/AST and creatinine at baseline; repeat during therapy to monitor PEP tolerance.

Source Patient Testing

What to order

• HIV Ag/Ab (4th generation) with expedited turnaround; if known positive, consider current viral load to refine risk (does not replace PEP decisions at time zero).
• HBsAg for hepatitis B assessment.
• HCV antibody with reflex HCV RNA nucleic acid testing (NAT) for current infection.

Process and privacy

• Obtain consent and follow institutional policy and applicable laws.
• Document collection time, testing platform, and results; maintain strict confidentiality for the source patient.
• If the source cannot be tested promptly, manage as unknown risk and continue PEP as indicated.

Follow-Up Testing Procedures

Recommended schedule for the exposed worker

• HIV: repeat 4th-generation testing at ~6 weeks and 12 weeks after exposure (12 weeks is the usual final test). Extend to 6 months in special situations (e.g., immunosuppression or older assays).
• HCV: baseline antibody and ALT; HCV RNA at 3–6 weeks; final HCV antibody and ALT at 4–6 months.
• HBV: if not immune at exposure, complete the vaccine series and check anti-HBs 1–2 months after the last dose; if HBIG was given, defer anti-HBs testing until ≥6 months post-HBIG. Consider HBsAg at ~6 months to exclude infection after high-risk exposures.
• PEP safety labs: renal/hepatic function ~2 weeks after starting PEP and as clinically indicated.

During-PEP counseling

• Emphasize strict adherence for the full 28 days and prompt reporting of side effects.
• Use barrier protection for sexual activity and avoid blood, tissue, or semen donation until final HIV testing is negative.
• Discuss pregnancy and breastfeeding considerations with a clinician if relevant.

Documentation and closure

• Ensure all Sharps Injury Reporting forms, lab results, and immunization updates are filed.
• Confirm final Serological Testing outcomes and clear return-to-work guidance per policy.
• Participate in a brief incident review to reinforce Infection Control Measures and prevent recurrence.

Summary

Act fast: cleanse, report, and start PEP within hours when indicated. Combine a 28‑day Antiretroviral Regimen for HIV risk, timely HBIG/vaccination for HBV, and early HCV detection. Coordinate rapid source testing and complete all follow-up Serological Testing to close the loop safely and confidently.

FAQs

What are the immediate steps after a needlestick injury?

Secure the device without recapping, wash the site with soap and water (or irrigate mucous membranes with water/saline), avoid squeezing or caustic agents, cover the area, and report the incident to occupational health immediately while documenting key exposure details.

When should post-exposure prophylaxis be started?

Initiate HIV PEP as soon as possible—ideally within 2 hours and generally not later than 72 hours. Do not wait for source patient results; you can discontinue PEP if the source is later confirmed negative.

How is source patient testing conducted?

With appropriate consent and per policy, order HIV Ag/Ab (4th gen), HBsAg, and HCV antibody with reflex RNA. Expedite processing, document results, and maintain confidentiality; if results are delayed or the source is unavailable, manage as unknown risk.

What follow-up testing is required after exposure?

For the exposed worker, repeat HIV testing at ~6 and 12 weeks (extend to 6 months if needed); check HCV RNA at 3–6 weeks with final antibody/ALT at 4–6 months; and, if not immune to HBV, complete vaccination and verify anti-HBs 1–2 months after the final dose (≥6 months after HBIG if given), with additional HBV serology as indicated.